$BNGO 35% Upside for Bionano GenomicsMaxim Group analyst Jason McCarthy assigned a Buy rating to BioNano Genomics (BNGO) yesterday and set a price target of $2.00. The company’s shares closed last Tuesday at $0.83, close to its 52-week low of $0.25.
BioNano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. The company was founded by Han Cao in October 2003 and is headquartered in San Diego, CA.
